Metabolic plasticity in cancer has been linked to the development of drug-tolerant populations. In this issue of Science Signaling, Goldman et al integrate metabolic plasticity with phenotypic state transitions to examine how this reprogramming can be therapeutically exploited.
Copyright © 2019 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.